← Tommy Lawhorne has no comment.
The NCAA takes a shot at shot taking.
The NCAA Football Rules Committee took steps to further protect student-athletes by proposing a rule to eject players who target and contact defenseless players above the shoulders.
The committee, which met Monday-Wednesday, unanimously voted to increase the on-field penalty for targeting. The penalty, if approved by the Playing Rules Oversight Panel, will be a 15-yard penalty and automatic ejection of the player. The Panel meets on March 6 to review the proposals and membership comment.
More at stake means more pressure on the officials. Not that we should worry about that. Rogers Redding knows we shouldn't sweat it.
Yes, if there's one thing this past SEC season showed us, it's that there's a general consensus about making the right call.
Redding is a funny man.
One other proposed change isn't going to be good for the genius' blood pressure.
Another area the committee has discussed in recent years deals with blocking below the waist. The past two years, the committee has adjusted rules governing these blocks in an attempt to remove some potentially dangerous plays from the game. The result has been a confusing and uneven rule that has not had the intended impact.
The proposed rule will focus on the block itself and allow these blocks in typical line play.
Previously, the position of the player at the snap changed whether or not the player could block below the waist legally.
Basically that sounds like a lineman gets one shot at a cut block and if he loses straight ahead positioning, that's all she wrote. That, in all honesty, should be easier for officials to follow. Expect to hear some whining from Johnson about this one if they start flagging it more.
Oh boy… Wait till Penny Wagers gets a hold of this one!
Do the once in a while head shots really matter that much? Do the Thomas Davis hits really matter that much? Isn't the elephant in the room the years of repetitive collision injuries?
I think that the major issue is attempting to limit the 1st concussion. A player that has already received one concussion, is at a greater risk in the future. I know, what about high school or pop warner football?
The automatic ejection addition to the targeting penalty will give the SEC refs yet another way to control the outcome of games. Penn Wagers and Marc Curles are both beside themselves with glee. In a related development, the NCAA has now worked out an arrangement with the US Government where the referees can now send players and coaches to Federal prison without an indictment or trial simply by throwing a flag. There should be no problem as the general consensus is that the officials will make these calls properly.
You can trust us. After all, we're officials.
I heard that AJ Green actually targeted a DB from LSU a few years ago, but they did not eject him…hence the need for the rule change.
The SEC announced LSU will receive compensation through the implementation of this rule against against any UGA receiver of its choosing at any time during the 2013 regular season game. Georgia announced it will self-impose this penalty by suspending all of its receivers for the game.
Well at least they said the ejection could be reviewed on replay but it could only be overturned if the video clearly showed no illegal shot. Given that the average age of the video replay officials is older than dirt, I'm sure they will do there usual find job of never overturning anything.
So let's have a team's season ruined by a subjective penalty.
Can it be more subjective than the "celebration rule" ? Most of the rules applied in any football game are subjective and will vary from official to official. There are many more subjective rules that are egregious when compared to one that also involves a significant reason for believing it will promote measurable player safety. Just think of the "lost helmet" rule for a minute and this new rule change will grow more insignificant.
The correct question is "Will it change the field play such that it reduces the excitement level (therefore the reason for watching) of CFB" ? That is the only measure that this rule can be held to and my answer now is "No". Let's see how it plays out in the arena.
Maybe coaches will go back to the fundamentals of teaching the correct open field tackle. Head up. lead with the shoulder, wrap your arms, & run your legs through the tackle. Rep it over and over. The kids would realize this works better than taking a "kill shot" because they would miss fewer tackles too.
yep, but what about sportscenter?
Damn, half of the Florida defense would have been thrown out of the bowl game for the celebration of a tackle 30 yards downfield.
"Expect to hear some whining from Johnson…" I'm sorry, was there more to that sentence?
This plays right into the PJ's hands. Now he has an excuse…"The rule change took away my offensive scheme just as I had GT on the verge of offensive perfection". He's got an "out"…and he will exploit it. It will take him three years to overhaul his offense to the spread…and now he has Kennesaw State to deal with on the recruiting trail. Poor little Pj.
Yep. He's staying away from that juggernaut, Appalachian St.
I doubt we see many people tossed out of games….just like I have yet to see a taunting penalty enforced in the field of play and bring back a touchdown.
I can't tell if that is sarcasm or not (and if it is, my apologies).
But didn't the LSU punter get his TD called back for taunting? Granted, that's the only case of a called back TD that I can remember regarding the new taunting rule, but still, it happened.
You would be correct sir.
And it was a weak taunt at that.
Even moreso , a taunt has no smell.
I get the point of having some serious rules for targeting, but I don't like the idea of having it result in an ejection on a whim (even if it is reviewed on replay). They ought to leave it as a flag, and then let it be up to the conference/NCAA/whatever to decide after the game whether that player is suspended for the following game. I can already picture incredibly angry FisheriesDawg after one of our starting safeties is thrown out of the Auburn game for a relatively inconsequential hit. Besides, if you just eject them in-game, there isn't a whole lot of penalty to target in the fourth quarter.
Regarding your last sentence… isn't there already a rule about a player being ejected late in a game being ineligible for some or all of the next game?
I think we'll see more injured DBs from this. DBs will drop their heads to make lower tackles and have a higher incidence of neck, shoulder injuries.


text:
Online ShopMy Plansee
Online ShopMy PlanseePlansee Group
Supplier awards: Plansee honored three times
The Plansee team was recently honoured to receive three awards from key customers: AMEC, Texas Instruments and Sony presented Plansee with Supplier Awards for their excellent support in 2019.
This goes to show once again that Plansee is the first-choice supplier for its customers. Proven expertise, high quality, outstanding work and reliability are what characterize Plansee as a manufacturer. It is exactly these factors that play a decisive role in the semiconductor industry.
AMEC is a global micro-fabrication equipment company serving customers in the semiconductor industry and related high-tech sectors, based in China. Plansee has been supplying the company with various products for MOCVD since 2017, including Re outer heaters, Mo liners, spindles and filaments. The excellent properties of the products and their consistently high quality made Plansee the preferred supplier for AMEC.
Texas Instruments (TI) is a US technology company that designs, manufactures and sells semiconductors and various integrated circuits worldwide. Texas Instruments has been a customer of Plansee for many years now. TI Asia has now presented Plansee with the "Regional Supplier Recognition Award" in recognition of its outstanding performance in the areas of cost, environmental and social responsibility, technology, responsiveness, delivery reliability and quality.
Sony is a global company specializing in consumer and professional electronics, semiconductors, gaming, entertainment, and financial services. Sony has been a longstanding customer of Plansee, purchasing semiconductor and MOCVD products. Plansee and its sales partner TCS were awarded the breakthrough prize by Sony for the development of a W-liner source, which extends the source service life and reduces the costs for their CIS process.
The entire Plansee Management team would like to thank AMEC, TI and Sony for the award, as well as thank all employees who contributed to this success.
CareerAbout usProduction locationsMy PlanseeOnline Shop
Copyright © Plansee SE 2021

redpajama_set_name: RedPajamaCommonCrawl


text:
Attention pro-lifers! Can we afford to ignore the obvious?
Being pro-life means more than just standing up against abortion. Being pro-life means advocating for each and every human person — born and preborn. It means taking care of the infirm, the elderly, the disabled, the sick, and the preborn — no matter the age. We take care of each and every human being because they are human beings and are created in the image and likeness of God. Today's commentary addresses the many ways in which some people forget the true meaning of being pro-life, and it cautions us against falling into this insidious trap.
Biotechnology has made drastic advances over the past few years. This fairly new specialty which, oddly enough, began with the study of the fermentation process associated with brewing beer, is today all about genetic engineering — be it of plants or human beings. Biotechnology encompasses everything from making a baby in a test tube to creating a human being like Superman through the use of nanotechnology.
Yet, the politically motivated wing of the pro-life movement seems to be eerily silent on the new and perhaps more threatening aspects of a field that treats the human person as nothing more than a science lab where cells can be mutated, exchanged, taken at the cost of a human being's life, or manipulated to weed out the imperfect, the undesirable, and the weak. Wesley J. Smith called attention to this scientific threat to human dignity when he wrote, "The so-called 'quality of life ethic' . . . presumes to invidiously declare differing moral values for human life based on measurements of individual capacities or abilities." It has replaced the respect for human dignity ethic that was once the norm.
This is certainly obvious today, but as Christian writer and theologian John Kilner wishes to make clear, biotechnology need not be viewed as a science which we must oppose no matter what. During an interview he wisely said, "Biotechnology can be intended for good or ill — to enhance an appropriate stewardship over the created world or to assert ourselves at the expense of other people or other aspects of the created world. Accordingly, it can be a wonderful gift of God, but it is not necessarily so. . . . What's needed today is a balanced (biblically sound) view that takes the creation and redemption mandates — together with sinful human nature — seriously."
And that is my point exactly. As pro-life leaders, we have an obligation to explain why it is that manipulating the human being by way of practices such as contraception, in vitro fertilization, human embryonic stem cell research, vital organ transplantation, and the abusive use of palliative medicine are wrong and must be re-evaluated according to the laws of nature as established by God and his commandments. We must not apologize for our confidence in the Lord's perfect plan, but rather help those who doubt or refuse to respect it see that only good can come from being faithful to truth while nothing but evil results otherwise.
John Stonestreet did a great job of putting this all together in his must-read article, "The New Pro-Life: Time for an Upgrade." Writing about one of his latest BreakPoint This Week radio programs, he suggested a total upgrade in pro-life apologetics:
It's time Christians catch up and become what Scott Rae — my other guest this weekend — calls "Pro-Life 3.0."
According to Dr. Rae, a professor of ethics at Talbot School of Divinity, most churches are Pro-life 1.0, in other words, we're up to speed on the taking of life: we tend to stand against abortion and euthanasia. And some of us are up to speed or at least getting up to speed on pro-life 2.0, or the making of life. This includes challenges surrounding fertility treatments like IVF and surrogacy. (But we still have a long way to go on this one. I mean, how many young married couples, even in our churches, utilize in vitro fertilization without realizing they've created excess embryos that will either be discarded, abandoned, or selectively aborted? And how many know which birth control pills are abortive and which are not?)
But we now face issues not only concerning the making and taking of life, but of remaking life. The astounding speed of technology allows us to use what was intended for healing diseases or sickness to enhance or improve people. And as we've mentioned before here on BreakPoint (www.breakpoint.org), this brings with it the threat of eugenics.
It is not enough to be "anti-abortion." Nor can we continue to isolate this one murderous act from all the other threats to human dignity by suggesting that if a political candidate is "opposed to abortion," then he or she is pro-life. No!
We must expect those in whom we invest our trust and our vote to understand the fullness of truth. If they don't, we must do all we can to educate them. Lives are at stake! Ignoring the obvious makes us as guilty as those advocating biotechnological disregard for human beings.


Mega Sushi opened last year in Steveston Village near Gary Point Park. It's not exactly in the village area, so it's quite hidden unless you are on your way to Gary Point Park. Parking is limited in front of the restaurant itself, but there are quite a few free street parking across and nearby the restaurant.
We were greeted in Japanese by the waitress, but J told me they were Korean. And yes, we ended up learning that they could speak Korean. So I guess it's not exactly authentic Japanese food. The place was quite busy on the weekday for lunch and was slowly packed with people.
The nigiri sushi were presented nicely on the plate. They were fresh and the rice was just the perfect amount. I normally only eat salmon, but it was nice to give some of the other fish a try. The Red Tuna had a softer texture, and since I enjoy fish that has more of a bite to it, I enjoyed the Hamachi which was closer to a salmon texture.
The Crispy'n Crunchy Roll was on their special roll menu, and it was essentially a dynamite roll with a twist to it. It was covered with crispy temkasu, and drizzled with a sweet and spicy sauce. It definitely had lots of crunch to it, but it still didn't feel too oily. The hint of spice was evened out with the sweetness of the sauce, so it wasn't too spicy.
We also got the Mega Roll which was also under the special roll menu. This roll had seaweed on the outside, and it was then covered with batter and lightly fried to golden. I twas topped with imitation crab mixed with a spicy mayo sauce. On the top, were tobiko and golden yellow deep fried lotus chips. The lotus chips were my favourite as they added a crunch to it! I found this roll to be a little more spicy than the previous. Definitely a mouthful of flavour.
Lastly, we were presented with a complementary dish to our surprise. The waitress said this was the Tuna Tataki Nigiri. A lightly seared tuna on top of rice, with a special sauce and topped with alfalfa sprouts. Quite delicious and a nice unexpected treat.
Overall, I was quite satisfied with Mega Sushi. Food and service was up to par and they have large variety of specialty rolls, which seem to be attracting customers these days. It's good to have another addition of Japanese food in the Steveston area.


We will prepare an account and send email with further instructions to you.
Remark: Our main goal is hospitality. Members travel and visit other members.
Please keep in mind that other members also might want to visit you and that you are able to offer appropriate accommodation.


text:
Box Office Voodoo
U.S Box Office Report - 13th - 15th April 2007
1. Disturbia - $23M - $23M
2. Blades of Glory - $14M - $90.1M
3. Meet the Robinsons - $12.1M - $72M
4. Perfect Stranger - $11.5M - $11.5M
5. Are We Done Yet? - $9.2M - $33M
6. Pathinder - $4.8M - $4.8M
7. Wild Hogs - $4.6M - $152.5M
8. The Reaping - $4.5M - $19.7M
9. 300 - $4.3M $- 200M
10. Grindhouse - $4.2M - $19.7M
Six new movies opened this week, with five of them in more than 1100 locations. This has only happened a handful of times in cinematic history and to be honest it doesn't really help anyone. The public find their choices distilled, the studios see their releases vying for attention amongst of a slew of other films and anything that appeared last week can struggle to recover or make more of a headway. It also means that up to six movies that could have been performing well find themselves sitting outside the top ten. As the chart ended up, three of the new releases didn't make the top ten.
The first upset of the week kicks off straight away. Disturbia, a Rear Window clone for the 00s comfortably takes the top spot. Expected to open in second place, perhaps even third, Disturbia displaces Blades of Glory and sees off Perfect Stranger, the Halle Berry/Bruce Willis thriller that was expected to get the top spot. Disturbia has been hyped pretty heavily via Myspace, MTV etc, with Shia Labeouf being pushed as the next big thing (he'll be seen next in Transformers in July and May 2008 in the fourth Indiana Jones movie) and that appears to have worked, bringing in the huge teen demographic and perhaps older audiences looking for a decent thriller. The movie was made cheaply and didn't need to worry about its target market comparing it to Rear Window. It won't stay at the top for long but as a launch product for Labeouf it has performed admirably.
In its third week Blades of Glory slips just one spot and may even see $100M during the coming week. For Ferrell, only Elf & Talledga Nights have taken more money. The movie cost $61M to make and may end up being one of the biggest comedies of the year, alongside Wild Hogs.
With little competition Meet The Robinsons continues to have the under 12 market to itself and was off just 27% from last weekend. The film won't do as well as Disney's previous entry Chicken Little but it was certainly no repeat of last year's March Disney movie 'The Wild'. Meet The Robinsons was retooled when Pixar joined forces with Disney and while it hasn't emulated the success of a Pixar movie, it's no letdown either.
Perfect Stranger opens in fourth place. This little hyped thriller appears to have been dropped into the schedule from out of nowhere - a nervous studio wanting to quickly offload a bit of a turkey? It's certainly a disappointing amount which ever way you look at it. Some of the thriller box office has obviously been taken by Disturbia. Looking further it appears people just weren't that interested in seeing Bruce Willis as a successful businessman who may have killed a friend of investigative reporter Halle Berry. Going undercover at Willis' company Berry enters into an online game of cat & mouse.
Bruce Willis has struggled these past few years (though he hasn't gone down the Wild Hogs path like John Travolta) and this lack of success might explain his return to the Die Hard franchise this summer. Not since Unbreakable has he had a bona fide hit (both Over The Hedge and Sin City had Willis as part of an ensemble cast). Halle Berry has done a little better thanks to her role in the X-Men franchise (though like Willis' movies, it could be argued that that was part of ensemble cast as well) and Die Another Day but she also chose Catwoman and to a lesser degree Gothika. The critical success of Monster's Ball seems a long way away.
Are We Done Yet? is off an impressive 35% from last weekend (when it needed its 5 day total to equal the take of Are We There Yet?) and will finish up with around $55M before leaving the charts. On a less packed week the film might have done better (and it's still way ahead of Grindhouse) but up against six new movies not to mention Blades of Glory, it was always going to have tough second week.
The long-delayed Pathfinder, starring Karl Urban as a Viking adopted by Native American Indians, performs the best of the four remaining new releases but still hardly sets the world alight. With takings so close it may still drop further down the chart once final numbers are released on Monday. Pathfinder's release reeks of contractual obligation. Now in its seventh weekend on the chart Wild Hogs crosses the $150M mark. Slowing in momentum the movie has been a resounding success for all concerned and still has a lucrative DVD market to come.
The Reaping is off a huge amount this week and only its location number has helped it stay in the top ten. Curiously the market that deserted it to see Grindhouse last week seemed to have had second thoughts about it. The Reaping will leave the top ten next week and be on DVD by July, probably in a unrated cut. An unusual choice for two-time Oscar winner Hilary Swank.
Meanwhile 300 crosses the $200M mark in its sixth weekend and probably its last in the top ten. Easily the biggest movie of the year so far, the success of the R-rated 300 should pave the way for an R-rated Watchman movie.
Last week's big disappointment Grindhouse just about manages to stay in the top ten but is off a whopping 63%. Rumours of the film being pulled and re-released as two separate films have spread like wildfire this week and Harvey Weinstein has made no bones about it being a serious disappointment. Grindhouse will leave the chart next week. Will it return?
So, those other three new releases - The Fast & The Furious knock off Redline is at eleven and like Pathfinder (and Slow Burn), probably only saw the inside of a cinema thanks to contractual obligations. Aqua Teen Hunger Force Colon Movie for Theatres was at just 700 locations yet managed $3M. Part of Cartoon Network's Adult Swim, Aqua Teen courted controversy recently after promo billboard hacks where mistaken for terrorist explosive devices. Curiously, the movie received some of the best reviews of the week. Finally, Slow Burn, a thriller made in 2005 and starring Ray Liotta entered the charts at no.16, making just $800k.
Posted by Box Office Voodoo at 04:26
U.S Box Office and 80s' Movie Reporter. Established 2002, writing weekly since 2005. 80 From the 80s seeks to be the definitive resource for 80s movies.
Follow @boxofficevoodoo
Subscribe To Box Office Voodoo
U.S Box Office Report - 29th - 31st May 2009
U.S Box Office Report - 22nd - 24th May 2009
U.S Box Office Report - 15th - 17th May 2009
U.S Box Office Report - 1st - 3rd May 2009
U.S Box Office Report - 3rd - 5th April 2009
U.S Box Office Report - 27th - 29th March 2009
U.S Box Office Report - 6th - 8th March 2009
U.S Box Office Report - 28th Feb - 1st March 2009
U.S Box Office Report - 20th - 22nd February 2009
U.S Box Office Report - 13th - 15th February 2009
U.S Box Office Report - 6th - 8th February 2009
U.S Box Office Report - 30th Jan - 1st Feb 2009
U.S Box Office Report - 23th - 25th January 2009
U.S Box Office Report - 9th - 11th January 2009
U.S Box Office Report - 2nd - 4th January 2009
U.S Box Office Report - Year End 2008
U.S Box Office Report - Christmas 2008
U.S Box Office Report - 19th - 21st December 2008
U.S Box Office Report - 12th - 14th December 2008
U.S Box Office Report - 5th - 7th December 2008
U.S Box Office Report - 28th - 30th November 2008
U.S Box Office Report - 21st - 23rd November 2008
U.S Box Office Report - 7th - 9th November 2008
U.S Box Office Report - 31st Oct - 2nd Nov 2008
U.S Box Office Report - 24th - 26th October 2008
U.S Box Office Report - 3rd - 5th October 2008
U.S Box Office Report - 26th - 28th September 2008...
U.S Box Office Report - 19th - 21st September 2008...
U.S Box Office Report - 5th - 7th September 2008
U.S Box Office Report - 29th - 31st August 2008
U.S Box Office Report - 22nd - 24th August 2008
U.S Box Office Report - 15th - 17th August 2008
U.S Box Office Report - 8th - 10th August 2008
U.S Box Office Report - 1st - 3rd August 2008
U.S Box Office Report - 25th - 27th July 2008
U.S Box Office Report - 4th - 6th July 2008
U.S Box Office Report - 27th - 29th June 2008
U.S Box Office Report - 20th - 22nd June 2008
U.S Box Office Report - 6th - 8th June 2008
U.S Box Office Report - 30th May - 1st June 2008
U.S Box Office Report - 9th - 11th May 2008
U.S Box Office Report - 2nd - 4th May 2008
U.S Box Office Report - 4th - 6th April 2008
U.S Box Office Report - 21st - 23th March 2008
U.S Box Office Report - 29th Feb - 2nd March 2008...
U.S Box Office Report - 22nd - 24th February 2008
U.S Box Office Report - 8th - 10th February 2008
U.S Box Office Report - 1st - 3rd February 2008
U.S Box Office Report - 21st - 23rd December 2007
U.S Box Office Report - 30th Nov - 2nd Dec 2007
U.S Box Office Report - 9th - 11th November 2007
U.S Box Office Report - 2nd - 4th November 2007
U.S Box Office Report - 21st - 23rd October 2007
U.S Box Office Report - 5th - 7th October 2007
U.S Box Office Report - 21st - 23rd September 2007...
U.S Box Office Report - 31st Aug - 1st Sept 2007
U.S Box Office Report - 3th - 5th August 2007
U.S Box Office Report - 20th - 22nd July 2007


I couldn't help but share my grandiose lust for the never-ending satisfaction of Chanel. The eyes are soaked up in tears for everything Chanel. Period.
Pricing these items can be a down-payment on a house, a car, college tuition, all of which are great investments, but so is a Chanel. I haven't wrapped my head around the piggy bank stage of this process but on any given day I will get serious and throw caution to the wind and be an owner of a Chanel bag and a pin and then a shoe or maybe a pin, then the bag, then the shoe. Who knows?? But please do indulge me and share in my lust for a moment. Thank you.
Oh and in case you are you are lusting for the iphone case pictured above, here she is!


Zoledronic acid monohydrate is a white crystalline powder. Its molecular formula is C5H10N2O7P2 • H2O and a molar mass of 290.1 g/Mol. Zoledronic acid monohydrate is highly soluble in 0.1N sodium hydroxide solution, sparingly soluble in water and 0.1N hydrochloric acid, and practically insoluble in organic solvents. The pH of the Reclast solution for infusion is approximately 6.0 - 7.0.
Reclast is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, diagnosed by bone mineral density (BMD) or prevalent vertebral fracture, Reclast reduces the incidence of fractures (hip, vertebral and non-vertebral osteoporosis-related fractures). In patients at high risk of fracture, defined as a recent low-trauma hip fracture, Reclast reduces the incidence of new clinical fractures [see Clinical Studies].
Reclast is indicated for prevention of osteoporosis in postmenopausal women [see Clinical Studies].
Reclast is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies].
Reclast is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months [see Clinical Studies].
Reclast is indicated for treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget's disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see Clinical Studies].
Patients must be appropriately hydrated prior to administration of Reclast [see WARNINGS AND PRECAUTIONS].
After a single treatment with Reclast in Paget's disease an extended remission period is observed. Specific re-treatment data are not available. However, re-treatment with Reclast may be considered in patients who have relapsed, based on increases in serum alkaline phosphatase, or in those patients who failed to achieve normalization of their serum alkaline phosphatase, or in those patients with symptoms, as dictated by medical practice.
Prior to administration of each dose of Reclast, obtain a serum creatinine and creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each Reclast dose. Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment. A 5 mg dose of Reclast administered intravenously is recommended for patients with creatinine clearance greater than or equal to 35 mL/min. There are no safety or efficacy data to support the adjustment of the Reclast dose based on baseline renal function. Therefore, no dose adjustment is required in patients with CrCl greater than or equal to 35 mL/min [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS].
A routine oral examination should be performed by the prescriber prior to initiation of Reclast treatment [see WARNINGS AND PRECAUTIONS].
Instruct patients being treated for Paget's disease of bone on the importance of calcium and vitamin D supplementation in maintaining serum calcium levels, and on the symptoms of hypocalcemia. All patients should take 1500 mg elemental calcium daily in divided doses (750 mg two times a day, or 500 mg three times a day) and 800 international units vitamin D daily, particularly in the 2 weeks following Reclast administration [see WARNINGS AND PRECAUTIONS].
If refrigerated, allow the refrigerated solution to reach room temperature before administration. After opening, the solution is stable for 24 hours at 2°C-8°C (36°F-46°F) [see HOW SUPPLIED/Storage and Handling].
After opening the solution, it is stable for 24 hours at 2°C-8°C (36°F-46°F).
Treatment with intravenous bisphosphonates, including zoledronic acid, has been associated with renal impairment manifested as deterioration in renal function (i.e., increased serum creatinine) and in rare cases, acute renal failure. In the clinical trial for postmenopausal osteoporosis, patients with baseline creatinine clearance less than 30 mL/min (based on actual body weight), urine dipstick greater than or equal to 2+ protein or increase in serum creatinine of greater than 0.5 mg/dL during the screening visits were excluded. The change in creatinine clearance (measured annually prior to dosing) and the incidence of renal failure and impairment was comparable for both the Reclast and placebo treatment groups over 3 years, including patients with creatinine clearance between 30-60 mL/min at baseline. Overall, there was a transient increase in serum creatinine observed within 10 days of dosing in 1.8% of Reclast-treated patients versus 0.8% of placebo-treated patients which resolved without specific therapy [see WARNINGS AND PRECAUTIONS].
In the postmenopausal osteoporosis trial, Study 1, in 7736 patients, after initiation of therapy, symptoms consistent with ONJ occurred in one patient treated with placebo and one patient treated with Reclast. Both cases resolved after appropriate treatment [see WARNINGS AND PRECAUTIONS]. No reports of osteonecrosis of the jaw were reported in either treatment group in Study 2.
Creatinine clearance was measured annually prior to dosing and changes in long-term renal function over 24 months were comparable in the Reclast and active control groups [see WARNINGS AND PRECAUTIONS].
In this trial there were no cases of osteonecrosis of the jaw [see WARNINGS AND PRECAUTIONS].
The incidence of all-cause mortality was similar between treatment groups: 0.9% in the Reclast group and 0.7% in the active control group. The incidence of serious adverse events was similar between the Reclast treatment and prevention groups, 18.4% and 18.1%, respectively, and the active control treatment and prevention groups, 19.8% and 16.0%, respectively. The percentage of subjects who withdrew from the study due to adverse events was 2.2% in the Reclast group vs. 1.4% in the active control group. The overall safety and tolerability were similar between Reclast and active control groups with the exception of a higher incidence of post-dose symptoms in the Reclast group that occurred within 3 days after infusion. The overall safety and tolerability profile of Reclast in glucocorticoid-induced osteoporosis was similar to the adverse events reported in the Reclast postmenopausal osteoporosis clinical trial.
Renal function measured prior to dosing and at the end of the 12 month study was comparable in the Reclast and active control groups [see WARNINGS AND PRECAUTIONS].
In the Paget's disease trials, two 6-month, double-blind, comparative, multinational studies of 349 men and women aged greater than 30 years with moderate to severe disease and with confirmed Paget's disease of bone, 177 patients were exposed to Reclast and 172 patients exposed to risedronate. Reclast was administered once as a single 5 mg dose in 100 mL solution infused over at least 15 minutes. Risedronate was given as an oral daily dose of 30 mg for 2 months.
Adverse reactions occurring in at least 2% of the Paget's patients receiving Reclast (single 5 mg intravenous infusion) or risedronate (30 mg oral daily dose for 2 months) over a 6-month study period are listed by system organ class in Table 4.
In the Paget's disease trials, early, transient decreases in serum calcium and phosphate levels were observed. Approximately 21% of patients had serum calcium levels less than 8.4 mg/dL 9-11 days following Reclast administration.
In clinical trials in Paget's disease there were no cases of renal deterioration following a single 5 mg 15-minute infusion [see WARNINGS AND PRECAUTIONS].
Osteonecrosis of the jaw has been reported with zoledronic acid [see WARNINGS AND PRECAUTIONS].
Renal impairment has been observed following the administration of zoledronic acid in patients with pre-existing renal compromise or other risk factors [see WARNINGS AND PRECAUTIONS]. In patients with renal impairment, the exposure to concomitant medications that are primarily renally excreted (e.g., digoxin) may increase. Consider monitoring serum creatinine in patients at risk for renal impairment who are taking concomitant medications that are primarily excreted by the kidney.
Pre-existing hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) is highly recommended for these patients [see CONTRAINDICATIONS].
Hypocalcemia following Reclast administration is a significant risk in Paget's disease. All patients should be instructed about the symptoms of hypocalcemia and the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS, PATIENT INFORMATION].
All osteoporosis patients should be instructed on the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see DOSAGE AND ADMINISTRATION, ADVERSE REACTIONS, PATIENT INFORMATION].
A single dose of Reclast should not exceed 5 mg and the duration of infusion should be no less than 15 minutes [see DOSAGE AND ADMINISTRATION].
Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment [see CONTRAINDICATIONS]. If history or physical signs suggest dehydration, Reclast therapy should be withheld until normovolemic status has been achieved [see ADVERSE REACTIONS].
Reclast should be used with caution in patients with chronic renal impairment. Acute renal impairment, including renal failure, has been observed following the administration of zoledronic acid, especially in patients with pre-existing renal compromise, advanced age, concomitant nephrotoxic medications, concomitant diuretic therapy, or severe dehydration occurring before or after Reclast administration. Acute renal failure (ARF) has been observed in patients after a single administration. Rare reports of hospitalization and/or dialysis or fatal outcome occurred in patients with underlying moderate to severe renal impairment or with any of the risk factors described in this section [see ADVERSE REACTIONS]. Renal impairment may lead to increased exposure of concomitant medications and/or their metabolites that are primarily renally excreted [see DRUG INTERACTIONS].
Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each Reclast dose. Transient increase in serum creatinine may be greater in patients with impaired renal function; interim monitoring of creatinine clearance should be performed in at-risk patients. Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. These patients should have their fluid status assessed and be appropriately hydrated prior to administration of Reclast. Reclast should be used with caution with other nephrotoxic drugs [see DRUG INTERACTIONS]. Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney [see DRUG INTERACTIONS].
RECLAST SHOULD NOT BE USED DURING PREGNANCY. Reclast may cause fetal harm when administered to a pregnant woman. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant while on Reclast therapy [see Use in Specific Populations].
In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking bisphosphonates, including Reclast. The time to onset of symptoms varied from one day to several months after starting the drug. Consider withholding future Reclast treatment if severe symptoms develop. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate [see ADVERSE REACTIONS].
Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min [see CONTRAINDICATIONS].
Reclast should not be given if the patient is pregnant or plans to become pregnant, or if she is breast-feeding [see WARNINGS AND PRECAUTIONS].
After getting Reclast it is strongly recommended patients with Paget's disease take calcium in divided doses (for example, 2 to 4 times a day) for a total of 1500 mg calcium a day to prevent low blood calcium levels. This is especially important for the two weeks after getting Reclast [see WARNINGS AND PRECAUTIONS].
Adequate calcium and vitamin D intake is important in patients with osteoporosis and the current recommended daily intake of calcium is 1200 mg and vitamin D is 800 international units - 1000 international units daily. All patients should be instructed on the importance of calcium and vitamin D supplementation in maintaining serum calcium levels.
Standard lifetime carcinogenicity bioassays were conducted in mice and rats. Mice were given daily oral doses of zoledronic acid of 0.1, 0.5, or 2.0 mg/kg/day. There was an increased incidence of Harderian gland adenomas in males and females in all treatment groups (at doses greater than or equal to 0.002 times the human intravenous dose of 5 mg, based on a mg/m² comparison). Rats were given daily oral doses of zoledronic acid of 0.1, 0.5, or 2.0 mg/kg/day. No increased incidence of tumors was observed (at doses less than or equal to 0.1 times the human intravenous dose of 5 mg, based on a mg/m² comparison).
Female rats were given daily subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg beginning 15 days before mating and continuing through gestation. Effects observed in the high-dose group (equivalent to human systemic exposure following a 5 mg intravenous dose, based on an AUC comparison) included inhibition of ovulation and a decrease in the number of pregnant rats. Effects observed in both the mid-dose group and high-dose group (0.3 to 1 times human systemic exposure following a 5 mg intravenous dose, based on an AUC comparison) included an increase in pre-implantation losses and a decrease in the number of implantations and live fetuses.
In pregnant rats given daily subcutaneous dose of zoledronic acid during gestation, adverse fetal effects were observed at about 2 and 4 times human systemic exposure following a 5 mg intravenous dose (based on an AUC comparison). These adverse effects included increases in pre-and post-implantation losses, decreases in viable fetuses, and fetal skeletal, visceral, and external malformations.
In pregnant rabbits given daily subcutaneous doses of zoledronic acid during gestation at doses less than or equal to 0.4 times the anticipated human systemic exposure following a 5 mg intravenous dose (based on a mg/m² comparison) no adverse fetal effects were observed. Maternal mortality and abortion occurred in all treatment groups (at doses greater than or equal to 0.04 times the human 5 mg intravenous dose, based on a mg/m² comparison). Adverse maternal effects were associated with, and may have been caused by, drug-induced hypocalcemia [see Nonclinical Toxicology].
The safety and effectiveness of zoledronic acid was studied in a one-year active controlled trial of 152 pediatric subjects (74 receiving zoledronic acid). The enrolled population was subjects with severe osteogenesis imperfecta, aged 1 to 17 years, 55% male, 84% Caucasian, with a mean lumbar spine BMD of 0.431 gm/cm², which is 2.7 standard deviations below the mean for age-matched controls (BMD Z-score of -2.7). At one year, increases in BMD were observed in the zoledronic acid treatment group. However, changes in BMD in individual patients with severe osteogenesis imperfecta did not necessarily correlate with the risk for fracture or the incidence or severity of chronic bone pain. The adverse events observed with zoledronic acid use in children did not raise any new safety findings beyond those previously seen in adults treated for Paget's disease of bone and treatment of osteoporosis including osteonecrosis of the jaw (ONJ) and renal impairment. However, adverse reactions seen more commonly in pediatric patients included pyrexia (61%), arthralgia (26%), hypocalcemia (22%) and headache (22%). These reactions, excluding arthralgia, occurred most frequently within three days after the first infusion and became less common with repeat dosing. No cases of ONJ or renal impairment were observed in this study. Because of long-term retention in bone, Reclast should only be used in children if the potential benefit outweighs the potential risk.
Of the patients receiving Reclast in the osteoporosis study in men, glucocorticoid-induced osteoporosis, and Paget's disease studies, 83, 116, and 132 patients, respectively were 65 years of age or over, while 24, 29, and 68 patients, respectively were at least 75 years of age.
Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment. There are no safety or efficacy data to support the adjustment of the Reclast dose based on baseline renal function. Therefore, no dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min [see WARNINGS AND PRECAUTIONS, CLINICAL PHARMACOLOGY]. Risk of acute renal failure may increase with underlying renal disease and dehydration secondary to fever, sepsis, gastrointestinal losses, diuretic therapy, advanced age, etc. [see ADVERSE REACTIONS].
Single doses of Reclast should not exceed 5 mg and the duration of the intravenous infusion should be no less than 15 minutes [see DOSAGE AND ADMINISTRATION].
Creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see WARNINGS AND PRECAUTIONS].
Known hypersensitivity to zoledronic acid or any components of Reclast. Hypersensitivity reactions including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see ADVERSE REACTIONS].
In the osteoporosis treatment trial, the effect of Reclast treatment on markers of bone resorption (serum beta-Ctelopeptides [b-CTx]) and bone formation (bone specific alkaline phosphatase [BSAP], serum N-terminal propeptide of type I collagen [P1NP]) was evaluated in patients (subsets ranging from 517 to 1246 patients) at periodic intervals. Treatment with a 5 mg annual dose of Reclast reduces bone turnover markers to the pre-menopausal range with an approximate 55% reduction in b-CTx, a 29% reduction in BSAP and a 52% reduction in P1NP over 36 months. There was no progressive reduction of bone turnover markers with repeated annual dosing.
Single or multiple (every 28 days) 5-minute or 15-minute infusions of 2, 4, 8 or 16 mg zoledronic acid were given to 64 patients with cancer and bone metastases. The post-infusion decline of zoledronic acid concentrations in plasma was consistent with a triphasic process showing a rapid decrease from peak concentrations at end-of-infusion to less than 1% of Cmax 24 hours post infusion with population half-lives of t½α 0.24 hour and t½β 1.87 hours for the early disposition phases of the drug. The terminal elimination phase of zoledronic acid was prolonged, with very low concentrations in plasma between Days 2 and 28 post infusion, and a terminal elimination half-life t½γ of 146 hours. The area under the plasma concentration versus time curve (AUC0-24h) of zoledronic acid was dose proportional from 2 to 16 mg. The accumulation of zoledronic acid measured over three cycles was low, with mean AUC0-24h ratios for cycles 2 and 3 versus 1 of 1.13 ± 0.30 and 1.16 ± 0.36, respectively.
In 64 patients with cancer and bone metastases on average (± SD) 39 ± 16% of the administered zoledronic acid dose was recovered in the urine within 24 hours, with only trace amounts of drug found in urine post Day 2. The cumulative percent of drug excreted in the urine over 0-24 hours was independent of dose. The balance of drug not recovered in urine over 0-24 hours, representing drug presumably bound to bone, is slowly released back into the systemic circulation, giving rise to the observed prolonged low plasma concentrations. The 0-24 hour renal clearance of zoledronic acid was 3.7 ± 2.0 L/h.
Zoledronic acid clearance was independent of dose but dependent upon the patient's creatinine clearance. In a study in patients with cancer and bone metastases, increasing the infusion time of a 4 mg dose of zoledronic acid from 5 minutes (n=5) to 15 minutes (n=7) resulted in a 34% decrease in the zoledronic acid concentration at the end of the infusion ([mean ± SD] 403 ± 118 ng/mL vs. 264 ± 86 ng/mL) and a 10% increase in the total AUC (378 ± 116 ng x h/mL vs. 420 ± 218 ng x h/mL). The difference between the AUC means was not statistically significant.
Pediatrics: Reclast is not indicated for use in children [see Pediatric Use].
Renal Impairment: The pharmacokinetic studies conducted in 64 cancer patients represented typical clinical populations with normal to moderately-impaired renal function. Compared to patients with creatinine clearance greater than 80 mL/min (N=37), patients with creatinine clearance = 50-80 mL/min (N=15) showed an average increase in plasma AUC of 15%, whereas patients with creatinine clearance = 30-50 mL/min (N=11) showed an average increase in plasma AUC of 43%. No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min. Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, Use in Specific Populations].
Zoledronic acid is a potent inhibitor of osteoclastic bone resorption. In the ovariectomized rat, single IV doses of zoledronic acid of 4-500 mcg/kg (less than 0.1 to 3.5 times human exposure at the 5 mg intravenous dose, based on a mg/m² comparison) suppressed bone turnover and protected against trabecular bone loss, cortical thinning and the reduction in vertebral and femoral bone strength in a dose-dependent manner. At a dose equivalent to human exposure at the 5 mg intravenous dose, the effect persisted for 8 months, which corresponds to approximately 8 remodeling cycles or 3 years in humans.
In ovariectomized rats and monkeys, weekly treatment with zoledronic acid dose-dependently suppressed bone turnover and prevented the decrease in cancellous and cortical BMD and bone strength, at yearly cumulative doses up to 3.5 times the intravenous human dose of 5 mg, based on a mg/m² comparison. Bone tissue was normal and there was no evidence of a mineralization defect, no accumulation of osteoid, and no woven bone.
In female rats given subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg/day beginning 15 days before mating and continuing through gestation, the number of stillbirths was increased and survival of neonates was decreased in the mid-and high-dose groups (greater than or equal to 0.3 times the anticipated human systemic exposure following a 5 mg intravenous dose, based on an AUC comparison). Adverse maternal effects were observed in all dose groups (greater than or equal to 0.1 times the human systemic exposure following a 5 mg intravenous dose, based on an AUC comparison) and included dystocia and periparturient mortality in pregnant rats allowed to deliver. Maternal mortality was considered related to drug-induced inhibition of skeletal calcium mobilization, resulting in periparturient hypocalcemia. This appears to be a bisphosphonate class effect.
In pregnant rats given daily subcutaneous dose of zoledronic acid of 0.1, 0.2, or 0.4 mg/kg during gestation, adverse fetal effects were observed in the mid-and high-dose groups (about 2 and 4 times human systemic exposure following a 5 mg intravenous dose, based on an AUC comparison). These adverse effects included increases in pre-and post-implantation losses, decreases in viable fetuses, and fetal skeletal, visceral, and external malformations. Fetal skeletal effects observed in the high-dose group included unossified or incompletely ossified bones, thickened, curved or shortened bones, wavy ribs, and shortened jaw. Other adverse fetal effects observed in the high-dose group included reduced lens, rudimentary cerebellum, reduction or absence of liver lobes, reduction of lung lobes, vessel dilation, cleft palate, and edema. Skeletal variations were also observed in the low-dose group (about 1.2 times the anticipated human systemic exposure, based on an AUC comparison). Signs of maternal toxicity were observed in the high-dose group and included reduced body weights and food consumption, indicating that maximal exposure levels were achieved in this study.
In pregnant rabbits given subcutaneous doses of zoledronic acid of 0.01, 0.03, or 0.1 mg/kg/day during gestation (at doses less than or equal to 0.4 times the anticipated human systemic exposure following a 5 mg intravenous dose, based on a mg/m² comparison) no adverse fetal effects were observed. Maternal mortality and abortion occurred in all treatment groups (at doses greater than or equal to 0.04 times the human 5 mg intravenous dose, based on a mg/m² comparison). Adverse maternal effects were associated with, and may have been caused by, drug-induced hypocalcemia.
In the 3-year osteoporosis study, standing height was measured annually using a stadiometer. The Reclast group revealed less height loss compared to placebo (4.2 mm vs. 7.0 mm, respectively [p < 0.001]).
Reclast significantly increased lumbar spine BMD relative to placebo at Month 24 across both strata. Reclast given once at randomization (and placebo given at Month 12) resulted in 4.0% increase in BMD in Stratum I patients and 4.8% increase in Stratum II patients over 24 months. Placebo given at randomization and at Month 12 resulted in 2.2% decrease in BMD in Stratum I patients and 0.7% decrease in BMD in Stratum II patients over 24 months. Therefore, Reclast given once at randomization (and placebo given at Month 12) resulted in a 6.3% increase in BMD in Stratum I patients and 5.4% increase in Stratum II patients over 24 months as compared to placebo (both p < 0.0001).
Reclast also significantly increased total hip BMD relative to placebo at Month 24 across both strata. Reclast given once at randomization (and placebo given at Month 12) resulted in 2.6% increase in BMD in Stratum I patients and 2.1% in Stratum II patients over 24 months. Placebo given at randomization and at Month 12 resulted in 2.1% decrease in BMD in Stratum I patients and 1.0% decrease in BMD in Stratum II patients over 24 months. Therefore, Reclast given once at randomization (and placebo given at Month 12) resulted in a 4.7% increase in BMD in Stratum I patients and 3.2% increase in Stratum II patients over 24 months as compared to placebo (both p < 0.0001).
In the GIO treatment subpopulation, Reclast demonstrated a significant mean increase in lumbar spine BMD compared to the active control at one year (Reclast 4.1%, active control 2.7%) with a treatment difference of 1.4% (p < 0.001). In the GIO prevention subpopulation, Reclast demonstrated a significant mean increase in lumbar spine BMD compared to active control at one year (Reclast 2.6%, active control 0.6%) with a treatment difference of 2.0% (p < 0.001).
Reclast was studied in male and female patients with moderate to severe Paget's disease of bone, defined as serum alkaline phosphatase level at least twice the upper limit of the age-specific normal reference range at the time of study entry. Diagnosis was confirmed by radiographic evidence.
The 6-month combined data from both trials showed that 96% (169/176) of Reclast-treated patients achieved a therapeutic response as compared with 74% (127/171) of patients treated with risedronate. Most Reclast patients achieved a therapeutic response by the Day 63 visit. In addition, at 6 months, 89% (156/176) of Reclast-treated patients achieved normalization of SAP levels, compared to 58% (99/171) of patients treated with risedronate (p < 0.0001) (see Figure 2).
Bone histology was evaluated in 7 patients with Paget's disease 6 months after being treated with Reclast 5 mg. Bone biopsy results showed bone of normal quality with no evidence of impaired bone remodeling and no evidence of mineralization defect.
Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Certain medicines may affect how Reclast works.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. This Medication Guide summarizes the most important information about Reclast. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Reclast that is written for health professionals.


A STUDENT WAS IN POSSESSION OF MARIJUANA AT A HIGH SCHOOL IN EL DORADO. THIS REPORT WAS WRITTEN FOR INFORMATION ONLY.
MOTHER REPORTED HER ADULT TRANSIENT CHILD AS A MISSING PERSON. INCIDENT DOCUMENTED.
CONTACT FOR DISABLED VEHICLE / TRAFFIC HAZARD RESULTS IN ARREST FOR SUBJECT WANTED BY SLTPD FOR ADW.


text:
namespace variations {

namespace {

// Signature verification is disabled on mobile platforms for now, since it
// adds about ~15ms to the startup time on mobile (vs. a couple ms on desktop).
bool SignatureVerificationEnabled() {
#if defined(OS_IOS) || defined(OS_ANDROID)
  return false;
#else
  return true;
#endif
}

// The ECDSA public key of the variations server for verifying variations seed
// signatures.
const uint8_t kPublicKey[] = {
  0x30, 0x59, 0x30, 0x13, 0x06, 0x07, 0x2a, 0x86, 0x48, 0xce, 0x3d, 0x02, 0x01,
  0x06, 0x08, 0x2a, 0x86, 0x48, 0xce, 0x3d, 0x03, 0x01, 0x07, 0x03, 0x42, 0x00,
  0x04, 0x51, 0x7c, 0x31, 0x4b, 0x50, 0x42, 0xdd, 0x59, 0xda, 0x0b, 0xfa, 0x43,
  0x44, 0x33, 0x7c, 0x5f, 0xa1, 0x0b, 0xd5, 0x82, 0xf6, 0xac, 0x04, 0x19, 0x72,
  0x6c, 0x40, 0xd4, 0x3e, 0x56, 0xe2, 0xa0, 0x80, 0xa0, 0x41, 0xb3, 0x23, 0x7b,
  0x71, 0xc9, 0x80, 0x87, 0xde, 0x35, 0x0d, 0x25, 0x71, 0x09, 0x7f, 0xb4, 0x15,
  0x2b, 0xff, 0x82, 0x4d, 0xd3, 0xfe, 0xc5, 0xef, 0x20, 0xc6, 0xa3, 0x10, 0xbf,
};

// Note: UMA histogram enum - don't re-order or remove entries.
enum VariationSeedEmptyState {
  VARIATIONS_SEED_NOT_EMPTY,
  VARIATIONS_SEED_EMPTY,
  VARIATIONS_SEED_CORRUPT,
  VARIATIONS_SEED_INVALID_SIGNATURE,
  VARIATIONS_SEED_CORRUPT_BASE64,
  VARIATIONS_SEED_CORRUPT_PROTOBUF,
  VARIATIONS_SEED_CORRUPT_GZIP,
  VARIATIONS_SEED_EMPTY_ENUM_SIZE,
};

void RecordVariationSeedEmptyHistogram(VariationSeedEmptyState state) {
  UMA_HISTOGRAM_ENUMERATION("Variations.SeedEmpty", state,
                            VARIATIONS_SEED_EMPTY_ENUM_SIZE);
}

enum VariationsSeedStoreResult {
  VARIATIONS_SEED_STORE_SUCCESS,
  VARIATIONS_SEED_STORE_FAILED_EMPTY,
  VARIATIONS_SEED_STORE_FAILED_PARSE,
  VARIATIONS_SEED_STORE_FAILED_SIGNATURE,
  VARIATIONS_SEED_STORE_FAILED_GZIP,
  // DELTA_COUNT is not so much a result of the seed store, but rather counting
  // the number of delta-compressed seeds the SeedStore() function saw. Kept in
  // the same histogram for convenience of comparing against the other values.
  VARIATIONS_SEED_STORE_DELTA_COUNT,
  VARIATIONS_SEED_STORE_FAILED_DELTA_READ_SEED,
  VARIATIONS_SEED_STORE_FAILED_DELTA_APPLY,
  VARIATIONS_SEED_STORE_FAILED_DELTA_STORE,
  VARIATIONS_SEED_STORE_FAILED_UNGZIP,
  VARIATIONS_SEED_STORE_FAILED_EMPTY_GZIP_CONTENTS,
  VARIATIONS_SEED_STORE_FAILED_UNSUPPORTED_SEED_FORMAT,
  VARIATIONS_SEED_STORE_RESULT_ENUM_SIZE,
};

void RecordSeedStoreHistogram(VariationsSeedStoreResult result) {
  UMA_HISTOGRAM_ENUMERATION("Variations.SeedStoreResult", result,
                            VARIATIONS_SEED_STORE_RESULT_ENUM_SIZE);
}

// Note: UMA histogram enum - don't re-order or remove entries.
enum VariationsSeedDateChangeState {
  SEED_DATE_NO_OLD_DATE,
  SEED_DATE_NEW_DATE_OLDER,
  SEED_DATE_SAME_DAY,
  SEED_DATE_NEW_DAY,
  SEED_DATE_ENUM_SIZE,
};

// Truncates a time to the start of the day in UTC. If given a time representing
// 2014-03-11 10:18:03.1 UTC, it will return a time representing
// 2014-03-11 00:00:00.0 UTC.
base::Time TruncateToUTCDay(const base::Time& time) {
  base::Time::Exploded exploded;
  time.UTCExplode(&exploded);
  exploded.hour = 0;
  exploded.minute = 0;
  exploded.second = 0;
  exploded.millisecond = 0;

  return base::Time::FromUTCExploded(exploded);
}

VariationsSeedDateChangeState GetSeedDateChangeState(
    const base::Time& server_seed_date,
    const base::Time& stored_seed_date) {
  if (server_seed_date < stored_seed_date)
    return SEED_DATE_NEW_DATE_OLDER;

  if (TruncateToUTCDay(server_seed_date) !=
      TruncateToUTCDay(stored_seed_date)) {
    // The server date is earlier than the stored date, and they are from
    // different UTC days, so |server_seed_date| is a valid new day.
    return SEED_DATE_NEW_DAY;
  }
  return SEED_DATE_SAME_DAY;
}

#if defined(OS_ANDROID)
enum FirstRunResult {
  FIRST_RUN_SEED_IMPORT_SUCCESS,
  FIRST_RUN_SEED_IMPORT_FAIL_NO_CALLBACK,
  FIRST_RUN_SEED_IMPORT_FAIL_NO_FIRST_RUN_SEED,
  FIRST_RUN_SEED_IMPORT_FAIL_STORE_FAILED,
  FIRST_RUN_RESULT_ENUM_SIZE,
};

void RecordFirstRunResult(FirstRunResult result) {
  UMA_HISTOGRAM_ENUMERATION("Variations.FirstRunResult", result,
                            FIRST_RUN_RESULT_ENUM_SIZE);
}
#endif  // OS_ANDROID

}  // namespace

VariationsSeedStore::VariationsSeedStore(PrefService* local_state)
    : local_state_(local_state), seed_has_country_code_(false) {
}

VariationsSeedStore::~VariationsSeedStore() {
}

bool VariationsSeedStore::LoadSeed(variations::VariationsSeed* seed) {
  invalid_base64_signature_.clear();

#if defined(OS_ANDROID)
  if (!local_state_->HasPrefPath(prefs::kVariationsSeedSignature))
    ImportFirstRunJavaSeed();
#endif  // OS_ANDROID

  std::string seed_data;
  if (!ReadSeedData(&seed_data))
    return false;

  const std::string base64_seed_signature =
      local_state_->GetString(prefs::kVariationsSeedSignature);
  const VerifySignatureResult result =
      VerifySeedSignature(seed_data, base64_seed_signature);
  if (result != VARIATIONS_SEED_SIGNATURE_ENUM_SIZE) {
    UMA_HISTOGRAM_ENUMERATION("Variations.LoadSeedSignature", result,
                              VARIATIONS_SEED_SIGNATURE_ENUM_SIZE);
    if (result != VARIATIONS_SEED_SIGNATURE_VALID) {
      ClearPrefs();
      RecordVariationSeedEmptyHistogram(VARIATIONS_SEED_INVALID_SIGNATURE);
      // Record the invalid signature.
      invalid_base64_signature_ = base64_seed_signature;
      return false;
    }
  }

  if (!seed->ParseFromString(seed_data)) {
    ClearPrefs();
    RecordVariationSeedEmptyHistogram(VARIATIONS_SEED_CORRUPT_PROTOBUF);
    return false;
  }

  // Migrate any existing country code from the seed to the pref, if the pref is
  // empty. TODO(asvitkine): Clean up the code in M50+ when sufficient number
  // of clients have migrated.
  if (seed->has_country_code() &&
      local_state_->GetString(prefs::kVariationsCountry).empty()) {
    local_state_->SetString(prefs::kVariationsCountry, seed->country_code());
  }
  variations_serial_number_ = seed->serial_number();
  seed_has_country_code_ = seed->has_country_code();
  RecordVariationSeedEmptyHistogram(VARIATIONS_SEED_NOT_EMPTY);
  return true;
}

bool VariationsSeedStore::StoreSeedData(
    const std::string& data,
    const std::string& base64_seed_signature,
    const std::string& country_code,
    const base::Time& date_fetched,
    bool is_delta_compressed,
    bool is_gzip_compressed,
    variations::VariationsSeed* parsed_seed) {
  // If the data is gzip compressed, first uncompress it.
  std::string ungzipped_data;
  if (is_gzip_compressed) {
    if (compression::GzipUncompress(data, &ungzipped_data)) {
      if (ungzipped_data.empty()) {
        RecordSeedStoreHistogram(
            VARIATIONS_SEED_STORE_FAILED_EMPTY_GZIP_CONTENTS);
        return false;
      }

      int size_reduction = ungzipped_data.length() - data.length();
      UMA_HISTOGRAM_PERCENTAGE("Variations.StoreSeed.GzipSize.ReductionPercent",
                               100 * size_reduction / ungzipped_data.length());
      UMA_HISTOGRAM_COUNTS_1000("Variations.StoreSeed.GzipSize",
                                data.length() / 1024);
    } else {
      RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_FAILED_UNGZIP);
      return false;
    }
  } else {
    ungzipped_data = data;
  }

  if (!is_delta_compressed) {
    const bool result =
        StoreSeedDataNoDelta(ungzipped_data, base64_seed_signature,
                             country_code, date_fetched, parsed_seed);
    if (result) {
      UMA_HISTOGRAM_COUNTS_1000("Variations.StoreSeed.Size",
                                ungzipped_data.length() / 1024);
    }
    return result;
  }

  // If the data is delta compressed, first decode it.
  DCHECK(invalid_base64_signature_.empty());
  RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_DELTA_COUNT);

  std::string existing_seed_data;
  std::string updated_seed_data;
  if (!ReadSeedData(&existing_seed_data)) {
    RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_FAILED_DELTA_READ_SEED);
    return false;
  }
  if (!ApplyDeltaPatch(existing_seed_data, ungzipped_data,
                       &updated_seed_data)) {
    RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_FAILED_DELTA_APPLY);
    return false;
  }

  const bool result =
      StoreSeedDataNoDelta(updated_seed_data, base64_seed_signature,
                           country_code, date_fetched, parsed_seed);
  if (result) {
    // Note: |updated_seed_data.length()| is guaranteed to be non-zero, else
    // result would be false.
    int size_reduction = updated_seed_data.length() - ungzipped_data.length();
    UMA_HISTOGRAM_PERCENTAGE("Variations.StoreSeed.DeltaSize.ReductionPercent",
                             100 * size_reduction / updated_seed_data.length());
    UMA_HISTOGRAM_COUNTS_1000("Variations.StoreSeed.DeltaSize",
                              ungzipped_data.length() / 1024);
  } else {
    RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_FAILED_DELTA_STORE);
  }
  return result;
}

void VariationsSeedStore::UpdateSeedDateAndLogDayChange(
    const base::Time& server_date_fetched) {
  VariationsSeedDateChangeState date_change = SEED_DATE_NO_OLD_DATE;

  if (local_state_->HasPrefPath(prefs::kVariationsSeedDate)) {
    const int64_t stored_date_value =
        local_state_->GetInt64(prefs::kVariationsSeedDate);
    const base::Time stored_date =
        base::Time::FromInternalValue(stored_date_value);

    date_change = GetSeedDateChangeState(server_date_fetched, stored_date);
  }

  UMA_HISTOGRAM_ENUMERATION("Variations.SeedDateChange", date_change,
                            SEED_DATE_ENUM_SIZE);

  local_state_->SetInt64(prefs::kVariationsSeedDate,
                         server_date_fetched.ToInternalValue());
}

std::string VariationsSeedStore::GetInvalidSignature() const {
  return invalid_base64_signature_;
}

// static
void VariationsSeedStore::RegisterPrefs(PrefRegistrySimple* registry) {
  registry->RegisterStringPref(prefs::kVariationsCompressedSeed, std::string());
  registry->RegisterStringPref(prefs::kVariationsSeed, std::string());
  registry->RegisterInt64Pref(prefs::kVariationsSeedDate,
                              base::Time().ToInternalValue());
  registry->RegisterStringPref(prefs::kVariationsSeedSignature, std::string());
  registry->RegisterStringPref(prefs::kVariationsCountry, std::string());
}

VariationsSeedStore::VerifySignatureResult
VariationsSeedStore::VerifySeedSignature(
    const std::string& seed_bytes,
    const std::string& base64_seed_signature) {
  if (!SignatureVerificationEnabled())
    return VARIATIONS_SEED_SIGNATURE_ENUM_SIZE;

  if (base64_seed_signature.empty())
    return VARIATIONS_SEED_SIGNATURE_MISSING;

  std::string signature;
  if (!base::Base64Decode(base64_seed_signature, &signature))
    return VARIATIONS_SEED_SIGNATURE_DECODE_FAILED;

  crypto::SignatureVerifier verifier;
  if (!verifier.VerifyInit(crypto::SignatureVerifier::ECDSA_SHA256,
                           reinterpret_cast<const uint8_t*>(signature.data()),
                           signature.size(), kPublicKey,
                           arraysize(kPublicKey))) {
    return VARIATIONS_SEED_SIGNATURE_INVALID_SIGNATURE;
  }

  verifier.VerifyUpdate(reinterpret_cast<const uint8_t*>(seed_bytes.data()),
                        seed_bytes.size());
  if (verifier.VerifyFinal())
    return VARIATIONS_SEED_SIGNATURE_VALID;
  return VARIATIONS_SEED_SIGNATURE_INVALID_SEED;
}

void VariationsSeedStore::ClearPrefs() {
  local_state_->ClearPref(prefs::kVariationsCompressedSeed);
  local_state_->ClearPref(prefs::kVariationsSeed);
  local_state_->ClearPref(prefs::kVariationsSeedDate);
  local_state_->ClearPref(prefs::kVariationsSeedSignature);
}

#if defined(OS_ANDROID)
void VariationsSeedStore::ImportFirstRunJavaSeed() {
  DVLOG(1) << "Importing first run seed from Java preferences.";

  std::string seed_data;
  std::string seed_signature;
  std::string seed_country;
  std::string response_date;
  bool is_gzip_compressed;

  android::GetVariationsFirstRunSeed(&seed_data, &seed_signature, &seed_country,
                                     &response_date, &is_gzip_compressed);
  if (seed_data.empty()) {
    RecordFirstRunResult(FIRST_RUN_SEED_IMPORT_FAIL_NO_FIRST_RUN_SEED);
    return;
  }

  base::Time current_date;
  base::Time::FromUTCString(response_date.c_str(), &current_date);

  if (!StoreSeedData(seed_data, seed_signature, seed_country, current_date,
                     false, is_gzip_compressed, nullptr)) {
    RecordFirstRunResult(FIRST_RUN_SEED_IMPORT_FAIL_STORE_FAILED);
    LOG(WARNING) << "First run variations seed is invalid.";
    return;
  }
  RecordFirstRunResult(FIRST_RUN_SEED_IMPORT_SUCCESS);
}
#endif  // OS_ANDROID

bool VariationsSeedStore::ReadSeedData(std::string* seed_data) {
  std::string base64_seed_data =
      local_state_->GetString(prefs::kVariationsCompressedSeed);
  const bool is_compressed = !base64_seed_data.empty();
  // If there's no compressed seed, fall back to the uncompressed one.
  if (!is_compressed)
    base64_seed_data = local_state_->GetString(prefs::kVariationsSeed);

  if (base64_seed_data.empty()) {
    RecordVariationSeedEmptyHistogram(VARIATIONS_SEED_EMPTY);
    return false;
  }

  // If the decode process fails, assume the pref value is corrupt and clear it.
  std::string decoded_data;
  if (!base::Base64Decode(base64_seed_data, &decoded_data)) {
    ClearPrefs();
    RecordVariationSeedEmptyHistogram(VARIATIONS_SEED_CORRUPT_BASE64);
    return false;
  }

  if (!is_compressed) {
    seed_data->swap(decoded_data);
  } else if (!compression::GzipUncompress(decoded_data, seed_data)) {
    ClearPrefs();
    RecordVariationSeedEmptyHistogram(VARIATIONS_SEED_CORRUPT_GZIP);
    return false;
  }

  return true;
}

bool VariationsSeedStore::StoreSeedDataNoDelta(
    const std::string& seed_data,
    const std::string& base64_seed_signature,
    const std::string& country_code,
    const base::Time& date_fetched,
    variations::VariationsSeed* parsed_seed) {
  if (seed_data.empty()) {
    RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_FAILED_EMPTY_GZIP_CONTENTS);
    return false;
  }

  // Only store the seed data if it parses correctly.
  variations::VariationsSeed seed;
  if (!seed.ParseFromString(seed_data)) {
    RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_FAILED_PARSE);
    return false;
  }

  const VerifySignatureResult result =
      VerifySeedSignature(seed_data, base64_seed_signature);
  if (result != VARIATIONS_SEED_SIGNATURE_ENUM_SIZE) {
    UMA_HISTOGRAM_ENUMERATION("Variations.StoreSeedSignature", result,
                              VARIATIONS_SEED_SIGNATURE_ENUM_SIZE);
    if (result != VARIATIONS_SEED_SIGNATURE_VALID) {
      RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_FAILED_SIGNATURE);
      return false;
    }
  }

  // Compress the seed before base64-encoding and storing.
  std::string compressed_seed_data;
  if (!compression::GzipCompress(seed_data, &compressed_seed_data)) {
    RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_FAILED_GZIP);
    return false;
  }

  std::string base64_seed_data;
  base::Base64Encode(compressed_seed_data, &base64_seed_data);

  // TODO(asvitkine): This pref is no longer being used. Remove it completely
  // in M45+.
  local_state_->ClearPref(prefs::kVariationsSeed);

#if defined(OS_ANDROID)
  // If currently we do not have any stored pref then we mark seed storing as
  // successful on the Java side of Chrome for Android to avoid repeated seed
  // fetches and clear preferences on the Java side.
  if (local_state_->GetString(prefs::kVariationsCompressedSeed).empty()) {
    android::MarkVariationsSeedAsStored();
    android::ClearJavaFirstRunPrefs();
  }
#endif

  // Update the saved country code only if one was returned from the server.
  // Prefer the country code that was transmitted in the header over the one in
  // the seed (which is deprecated).
  if (!country_code.empty())
    local_state_->SetString(prefs::kVariationsCountry, country_code);
  else if (seed.has_country_code())
    local_state_->SetString(prefs::kVariationsCountry, seed.country_code());

  local_state_->SetString(prefs::kVariationsCompressedSeed, base64_seed_data);
  UpdateSeedDateAndLogDayChange(date_fetched);
  local_state_->SetString(prefs::kVariationsSeedSignature,
                          base64_seed_signature);
  variations_serial_number_ = seed.serial_number();
  if (parsed_seed)
    seed.Swap(parsed_seed);

  RecordSeedStoreHistogram(VARIATIONS_SEED_STORE_SUCCESS);
  return true;
}

// static
bool VariationsSeedStore::ApplyDeltaPatch(const std::string& existing_data,
                                          const std::string& patch,
                                          std::string* output) {
  output->clear();

  google::protobuf::io::CodedInputStream in(
      reinterpret_cast<const uint8_t*>(patch.data()), patch.length());
  // Temporary string declared outside the loop so it can be re-used between
  // different iterations (rather than allocating new ones).
  std::string temp;

  const uint32_t existing_data_size =
      static_cast<uint32_t>(existing_data.size());
  while (in.CurrentPosition() != static_cast<int>(patch.length())) {
    uint32_t value;
    if (!in.ReadVarint32(&value))
      return false;

    if (value != 0) {
      // A non-zero value indicates the number of bytes to copy from the patch
      // stream to the output.

      // No need to guard against bad data (i.e. very large |value|) because the
      // call below will fail if |value| is greater than the size of the patch.
      if (!in.ReadString(&temp, value))
        return false;
      output->append(temp);
    } else {
      // Otherwise, when it's zero, it indicates that it's followed by a pair of
      // numbers - |offset| and |length| that specify a range of data to copy
      // from |existing_data|.
      uint32_t offset;
      uint32_t length;
      if (!in.ReadVarint32(&offset) || !in.ReadVarint32(&length))
        return false;

      // Check for |offset + length| being out of range and for overflow.
      base::CheckedNumeric<uint32_t> end_offset(offset);
      end_offset += length;
      if (!end_offset.IsValid() || end_offset.ValueOrDie() > existing_data_size)
        return false;
      output->append(existing_data, offset, length);
    }
  }
  return true;
}

void VariationsSeedStore::ReportUnsupportedSeedFormatError() {
  RecordSeedStoreHistogram(
      VARIATIONS_SEED_STORE_FAILED_UNSUPPORTED_SEED_FORMAT);
}

}  // namespace variations

redpajama_set_name: RedPajamaGithub


The name Nokia seems to be synonymous with exploding phones these days. Last week another woman was sent to hospital with light injuries after the battery of her Nokia mobile phone exploded.
There have been more 20 such incidents in the last year, according to Nokia. But the batteries in all exploding phones were non-original replacements made by unauthorised third-parties, the company says.
But now the Belgian consumer watchdog Test-Aankoop claims that some Nokia batteries (in particular the Nokia BML-3, BMC-3 and BLC-2) are also unprotected against short-circuiting.
The BML-3 was sold for the now-defunct Nokia 3210, the BMC 3 is still available for the Nokia 3310 and 3330 models; the BLC-2 is the default battery for the 3510, 3510i, 5510, 6650 and 6800 models. Test Aankoop has examined all these batteries and says Nokia needs to replace them at no extra cost.
But Nokia says these claims are "false". All Nokia batteries are designed and manufactured adhering to stringent safety and quality measures, including short circuit protection, Nokia said in a statement notably short of detail. According to the company, all its batteries adhere to "very strict requirements regarding the materials and insulation used, in addition to continuous production control and intensive product testing' and Nokia and its suppliers invest a great deal in research and development to "constantly safeguard and improve the quality and safety in all Nokia products."


Twice a year, BCS' IT department participates in a "Hackathon" that allows employees two days off to spend time honing their craft. Participants can use the time to learn new technologies, address a nagging problem, or innovate new concepts and ideas to better the business.
These events provide opportunities for innovation, imagination, and initiative, and help further our company and our culture.


text:
Q: Tuning Performance for Java on Linux and MariaDB I built a java program that connects to a local server and pulls information, then puts it in a mysql database (using jdbc and prepared statements). The program also creates many threads to do this. On the programming environment on my Mac OSX, it runs at a great speed with a single 2.3 ghz processor. I have now moved it to a VPS, installed mariaDB and the VPS has 3gb of ram, and 2 2.4ghz processors, but it runs slower than on my mac. What can I do to fix this? I installed alternative JVM's on the linux, I have used visualVM to optimize it. I just can't seem to figure out why creating these threads happens so fast on my mac while running other programs and on this VPS it is extremely slow.
Any help or direction would be a big help!

A: It sounds like your waiting on io from the db.  The latency between you and the db is much higher when the db is on a separate machine and has to make its way across a network.
Possible solutions...
Put the db on the same server as the app that's using it, (possibly increasing the memory of the box to accommodate.
That should fix it assuming you can get an appropriately sized box, (if it doesn't then optimizing the config of mysql/mariadb is advisable at that point)
If you need to leave it on separate servers because you are trying to scale horizontally, then consider processing the data in larger batches instead of making small individual sql queries that will incur allot of round trips to the db in a small amount of time.

redpajama_set_name: RedPajamaStackExchange


For a limited time, enjoy 15% off ALL products from New Dimension Towers.
Exact-fit wakeboard towers, biminis, wakeboard & water ski racks, hyrbid universal wakeboard towers, custom billet plates, wakeboard tower accessories and more.
To Order: Call (865)995-1000 or email Wayne@NewDimensionTowers.com.


text:
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">

<title>O-Index</title>
<meta name="date" content="2016-06-19">
<link rel="stylesheet" type="text/css" href="../stylesheet.css" title="Style">

JavaScript is disabled on your browser.

Overview

Package

Class

Tree

Deprecated

Index

Help

Prev Letter

Next Letter

Frames

No Frames

All Classes

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

O

objectIterator(ObjectInputStream) - Static method in class org.canova.api.berkeley.Iterators

oneItemIterator(U) - Static method in class org.canova.api.berkeley.Iterators

oneTailedFishersExact(int, int, int, int) - Static method in class org.canova.api.berkeley.SloppyMath

Find a one-tailed Fisher's exact probability.

onRecord(Collection<Writable>) - Method in interface org.canova.api.vector.Vectorizer.RecordCallBack

The record callback

open(InputStream) - Method in interface org.canova.api.io.serializers.Deserializer

Prepare the deserializer for reading.

open(OutputStream) - Method in interface org.canova.api.io.serializers.Serializer

Prepare the serializer for writing.

org.canova.api.berkeley - package org.canova.api.berkeley

org.canova.api.conf - package org.canova.api.conf

org.canova.api.exceptions - package org.canova.api.exceptions

org.canova.api.formats.input - package org.canova.api.formats.input

org.canova.api.formats.input.impl - package org.canova.api.formats.input.impl

org.canova.api.formats.output - package org.canova.api.formats.output

org.canova.api.formats.output.impl - package org.canova.api.formats.output.impl

org.canova.api.io - package org.canova.api.io

org.canova.api.io.converters - package org.canova.api.io.converters

org.canova.api.io.data - package org.canova.api.io.data

org.canova.api.io.filters - package org.canova.api.io.filters

org.canova.api.io.labels - package org.canova.api.io.labels

org.canova.api.io.serializers - package org.canova.api.io.serializers

org.canova.api.records - package org.canova.api.records

org.canova.api.records.listener - package org.canova.api.records.listener

org.canova.api.records.listener.impl - package org.canova.api.records.listener.impl

org.canova.api.records.reader - package org.canova.api.records.reader

org.canova.api.records.reader.factory - package org.canova.api.records.reader.factory

org.canova.api.records.reader.impl - package org.canova.api.records.reader.impl

org.canova.api.records.reader.impl.jackson - package org.canova.api.records.reader.impl.jackson

org.canova.api.records.reader.impl.regex - package org.canova.api.records.reader.impl.regex

org.canova.api.records.writer - package org.canova.api.records.writer

org.canova.api.records.writer.impl - package org.canova.api.records.writer.impl

org.canova.api.split - package org.canova.api.split

org.canova.api.util - package org.canova.api.util

org.canova.api.vector - package org.canova.api.vector

org.canova.api.writable - package org.canova.api.writable

org.canova.cli.csv.schema - package org.canova.cli.csv.schema

org.canova.cli.csv.statistics - package org.canova.cli.csv.statistics

org.canova.cli.csv.transforms - package org.canova.cli.csv.transforms

org.canova.cli.driver - package org.canova.cli.driver

org.canova.cli.formats.input - package org.canova.cli.formats.input

org.canova.cli.records.reader - package org.canova.cli.records.reader

org.canova.cli.shuffle - package org.canova.cli.shuffle

org.canova.cli.subcommands - package org.canova.cli.subcommands

org.canova.cli.transforms - package org.canova.cli.transforms

org.canova.cli.transforms.image - package org.canova.cli.transforms.image

org.canova.cli.transforms.text.nlp - package org.canova.cli.transforms.text.nlp

org.canova.cli.vectorization - package org.canova.cli.vectorization

org.canova.codec.format.input - package org.canova.codec.format.input

org.canova.codec.reader - package org.canova.codec.reader

org.canova.common - package org.canova.common

org.canova.common.data - package org.canova.common.data

org.canova.hadoop.conf - package org.canova.hadoop.conf

org.canova.hadoop.formats.input - package org.canova.hadoop.formats.input

org.canova.hadoop.records.reader - package org.canova.hadoop.records.reader

org.canova.image.data - package org.canova.image.data

org.canova.image.format - package org.canova.image.format

org.canova.image.loader - package org.canova.image.loader

org.canova.image.mnist - package org.canova.image.mnist

org.canova.image.mnist.draw - package org.canova.image.mnist.draw

org.canova.image.recordreader - package org.canova.image.recordreader

org.canova.image.transform - package org.canova.image.transform

org.canova.nd4j.nlp.input - package org.canova.nd4j.nlp.input

org.canova.nd4j.nlp.reader - package org.canova.nd4j.nlp.reader

org.canova.nd4j.nlp.vectorizer - package org.canova.nd4j.nlp.vectorizer

org.canova.nlp.annotator - package org.canova.nlp.annotator

org.canova.nlp.metadata - package org.canova.nlp.metadata

org.canova.nlp.movingwindow - package org.canova.nlp.movingwindow

org.canova.nlp.stopwords - package org.canova.nlp.stopwords

org.canova.nlp.tokenization.tokenizer - package org.canova.nlp.tokenization.tokenizer

org.canova.nlp.tokenization.tokenizer.preprocessor - package org.canova.nlp.tokenization.tokenizer.preprocessor

org.canova.nlp.tokenization.tokenizerfactory - package org.canova.nlp.tokenization.tokenizerfactory

org.canova.nlp.uima - package org.canova.nlp.uima

org.canova.nlp.vectorizer - package org.canova.nlp.vectorizer

org.canova.sound.formats.input - package org.canova.sound.formats.input

org.canova.sound.formats.output - package org.canova.sound.formats.output

org.canova.sound.musicg - package org.canova.sound.musicg

org.canova.sound.musicg.dsp - package org.canova.sound.musicg.dsp

Originally derived from musicg.

org.canova.sound.musicg.extension - package org.canova.sound.musicg.extension

org.canova.sound.musicg.fingerprint - package org.canova.sound.musicg.fingerprint

org.canova.sound.musicg.processor - package org.canova.sound.musicg.processor

org.canova.sound.musicg.properties - package org.canova.sound.musicg.properties

org.canova.sound.recordreader - package org.canova.sound.recordreader

org.canova.spark - package org.canova.spark

org.canova.spark.functions - package org.canova.spark.functions

org.canova.spark.functions.data - package org.canova.spark.functions.data

org.canova.spark.functions.pairdata - package org.canova.spark.functions.pairdata

org.canova.spark.util - package org.canova.spark.util

out - Variable in class org.canova.api.records.writer.impl.FileRecordWriter

OUTPUT_FILENAME_KEY - Static variable in class org.canova.cli.subcommands.Vectorize

OUTPUT_FORMAT - Static variable in class org.canova.cli.subcommands.Vectorize

OUTPUT_PATH - Static variable in interface org.canova.api.formats.output.OutputFormat

outputFilename - Variable in class org.canova.cli.vectorization.VectorizationEngine

OutputFormat - Interface in org.canova.api.formats.output

Create a record writer

outputFormat - Variable in class org.canova.cli.vectorization.VectorizationEngine

outputVectorFilename - Variable in class org.canova.cli.subcommands.Vectorize

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Overview

Package

Class

Tree

Deprecated

Index

Help

Prev Letter

Next Letter

Frames

No Frames

All Classes


text:
(Haiti)
Deliberate destruction of heritage
Impacts of tourism / visitor / recreation
Major visitor accommodation and associated infrastructure
Water (rain/water table)
Lack of a Management Plan;
Lack of a Conservation Plan;
Water damage;
Vandalism;
Seismic activities;
Infrastructure projects;
Lack of a Risk Preparedness Plan;
Potential non controlled touristic development
Total amount granted: USD 14,780 for the July 2010 Technical Mission partially funded by the Spanish Funds-in-Trust for World Heritage
Requests approved: 7 (from 1982-2010)
2010 Post Earthquake Technical Assistance for the Assessment ... (Approved) 49,300 USD
1994 New exhibition panels and purchase of climate control ... (Approved) 17,510 USD
1994 One-month on-site training activity for 5 architectural ... (Approved) 4,100 USD
1994 Emergency measures and structural consolidation of the ... (Approved) 73,000 USD
1987 Training courses at the National History Park-Citadel, ... (Approved) 25,000 USD
1983 Masonry work and purchase of equipment for the ... (Approved) 20,000 USD
1982 Equipment and construction material for the restoration ... (Approved) 57,200 USD
September 2006: UNESCO Havana Office Technical Visit; July 2010: Joint Expert Technical Mission; March 2011: UNESCO Preparatory Mission for Haiti Donor's Conference; January 2012: World Heritage Centre Technical Mission; March 2012: Multidisciplinary Technical Mission; May 2013 ICOMOS Mission; May 2013 Multidisciplinary Technical Mission.
2013 WHC / ICOMOS Technical Assistance Mission Report; National History Park – Citadel, Sans Souci, Ramiers; 15-22 July ...
2013 Multidisciplinary Technical Mission Report; National History Park – Citadel, Sans Souci, Ramiers, 14-29 May 2013
2012 Mission Report of the Survey (6-22 March 2012), Evaluation of the State of Conservation of the "National Historic ...
2006 Rapport de mission technique; Parc national historique – Citadelle, Sans Souci, Ramiers; 11-18 septembre 2006
A very brief report on the state of conservation of the property was submitted by the State Party on 13 February 2013, accompanied by a provisional Retrospective Statement of Outstanding Universal Value, prepared by the Institute for the Preservation of the National Heritage (ISPAN).
a) National Road RN003
The State Party confirmed the decision to respect the recommendations and warnings of ISPAN and the World Heritage Committee. The Ministry of Public Works invited a World Heritage Centre/Advisory Bodies technical mission in respect of the third section of the National Road RN003, funded by the European Union, to identify the final route and evaluate the project for improvement of the section between Milot and Dondon.
b) Roads in the National History Park
ISPAN began repair work and improvement to the roads in June 2012, between Sans-Souci and Choiseuil, from there to the Citadel and from there to Ramiers. These works responds to recommendations and drafted specifications taking into account the two missions in 2012, in order to enable the interventions. However, the secondary road project concerning the hills below the Citadel has not yet been implemented, although the road located between Ramiers and the Citadel has been improved. Some of the sections have been widened to improve drainage and for security reasons. Furthermore, between June and September 2012, ISPAN implemented a signage project, and road signs and information panels on the monuments were prepared and installed. The information panels of a historical and cultural nature concerning the Park and its monuments are graphic and multilingual.
c) Constructions in the National History Park
Two tourist constructions were built in the Park with the authorization of ISPAN. They concern a small pavilion at the main gate, where the church and the Sans-Souci Palace are located, and are destined to welcome and inform visitors. With regard to the welcome buildings at Choiseuil, they comprise stands for artists, information buildings, services and ramps for the horses. Two temporary structures were built and dismantled immediately after two brief events organized for the promotion of the Sans-Souci Palace. Thanks to private sector initiatives, the Sans-Souci church and its surrounds have undergone some repair work. Events such as the National Carnival in Cape Haitian were carried out to promote increased awareness of national heritage and cultural potential of the territory.
d) Conservation actions
Work has been carried out on the different floor levels of the Palace, such as cleaning up following rain damage and the installation of a mobile passage between the main stairs and the King's terrace. The access to the Coidavid Fort was closed on 23 March following the expertise of the technical and multidisciplinary mission. An important awareness-raising message to the public was addressed by ISPAN. On 16 July 2012 a violent storm heavily impacted Haiti and a part of the roof of the Coidavid Fort was damaged. The essential repair work has been completed. The Ministry of Tourism granted additional emergency funds to ISPAN in October 2012. The equivalent of USD 200,000 was used to consolidate the emergency work at Coidavid Fort in response to the recommendations of the multidisciplinary mission report of 2012. Another multidisciplinary mission is foreseen between April and May 2013, to develop, among others, recordings of typical damage at the Citadel, sampling and analysis of stonework, the establishment of a microclimate surveillance station and mechanical samplings at the Batteries; as well as planning a campaign to measure water distribution in the masonry by IR thermographic methods, biocidal treatment tests, photographic documentation of the reference zones and archaeological excavations in the courtyard of the Citadel. Individuation of security measures for the Batteries and verification of the efficiency of security measures for the Sans-Souci building will also be developed.
e) Cadastral study
A cadastral survey was initiated in June 2012. Between June and September, the agreement protocol between ISPAN and the Inter-ministerial Council for Territorial Development (CIAT) was updated. The difficulties encountered in 2011 were broached. Work at the site will be terminated at end-2013.
f) Cooperation between ISPAN, the Ministry of Culture and the Ministry of Tourism
Currently, since 16 August 2012, the State Party deals with an Inter-ministerial Commission comprising the Ministries of Culture, Tourism, Interior and Territorial Communities, and of Planning and External Cooperation, the mandate of which is to participate in the preparation and the implementation of national strategies for the management and development of the Park; to enforce the legal instruments and regulations for the management of the Park; to create and execute promotional programmes for culture, tourism, agriculture and the environment; to enhance ecotourism in liaison with territorial and local communities. The Ministries of Culture, Tourism and the Environment appointed the Director of the Park on 20 September 2012, and the Minister of Culture, Mario Dupuy, declared a National Heritage Day. Access to the Park was restricted and work coordinated by ISPAN, the Ministry of Culture and the Ministry of Tourism.
g) The World Bank
Following different meetings and discussions between the World Bank, the Ministry of Culture and the World Heritage Centre, it was decided to finance a World Heritage programme for the Citadel. This project will develop the capacities of ISPAN and result in a process of more rapid and secure decision-making for the conservation and management of the monuments of the Park. The Conservation Plan and management protocol are fully coherent with the emergency conservation operation. The immediate actions are to fund a Technical Unit at ISPAN, comprising a project coordinator, a junior architect-conservator, a junior engineer-conservator and an administrative assistant.
The World Heritage Centre and the Advisory Bodies observe that, although the State Party has begun, as far as it is possible to implement little by little the Committee decisions, it is extremely urgent to carry out an intervention to ensure the stabilisation of the structures that risk collapse. The conclusions of studies carried out and the diagnostics of components and structures have revealed the extreme vulnerability of the site, and the urgent measures to be undertaken are clearly identified in the recommendations.
The Order declaring the state of emergency throughout the territory and flagging up the particular status of the Park constitute a very positive measure. The World Heritage Centre and the Advisory Bodies recommend the finalization and approval of the Conservation Plan and consider essential to complete the implementation of the Conservation Plan as of December 2013.
Furthermore, the new government, in place since 24 January 2013, has promised to continue conservation and protection efforts for the National History Park, and to strengthen ISPAN's capacities. Thus, the Management Plan must be coherent with the Conservation Plan that has already been established. Finally, the World Heritage Centre and the Advisory Bodies insist upon the importance of establishing participatory mechanisms in the management for the site to improve the quality of life of the local population.
National History Park – Citadel, Sans Souci, Ramiers (Haiti) (C 180)
1. Having examined Document WHC-13/37.COM/7B.Add,
2. Recalling Decision 36 COM 7B.99, adopted at its 36th session (Saint-Petersburg, 2012),
3. Takes note of the information provided by the State Party, the World Heritage Centre and the World Bank concerning the measures undertaken to implement the decisions of the World Heritage Committee and acknowledges the efforts made by the Institute for the Preservation of National Heritage (ISPAN) to ensure the safeguarding of the property;
4. Thanks the Government of Spain and the Spanish Agency of International Development Cooperation for its generous contribution that enabled the continued implementation in 2013 of the Committee decisions;
5. Also takes note of the State Party's invitation for a World Heritage Centre/Advisory Bodies technical mission to examine the final project for the construction of the last section of National Road RN003, as well as the environmental, heritage and socio-economic impact studies on the site, and endorses the recommendations of the mission;
6. Requests the State Party to continue its efforts to complete the cadastral survey as well as the delineation of the boundaries and regulations of the buffer zone and to await the results of this study before proceeding with the physical marking out of the property and to facilitate the establishment of a participatory strategy for the conservation and management of the Park;
7. Further takes note of the latest results of the structural stabilization studies for the Citadel and urges the State Party to undertake the necessary measures to initiate emergency actions in cooperation with the technical and financial institutions to ensure the integrity of the fortified structures of the Citadel and Ramiers, as well as the Sans-Souci Palace;
8. Also requests the State Party to await the finalization and approval of the Conservation Plan before pursuing tourism development projects and further requests the participation of local communities in the conservation and management process for the site;
9. Requests furthermore the State Party to submit a study on visitor capacity levels for the Citadel, Ramiers and the Sans-Souci Palace to guarantee correct access conditions for visitors;
10. Requests, in addition, the State Party to submit by 30 December 2013 , the Action Plan relating to the project for the Citadel, coordinated by the World Heritage Centre in close collaboration with ISPAN;
11. Reiterates its request to the international community to ensure by every possible means, its support in the implementation of the recommendations to rapidly approve financial and human resources in order to assist the State Party to ensure the conservation of the entire property and in particular the quality of life of the inhabitants;
12. Finally requests the State Party to submit to the World Heritage Centre, by 1 February 2014 , an updated report on the state of conservation of the property and the implementation of the above recommendations, for examination by the World Heritage Committee at its 38th session in 2014.
4. Thanks the Government of Spain and the Spanish Agency of International Development Cooperation for its generous contribution that enabled the continued implementation in 2013 of the World Heritage Committee decisions;
10. Requests, in addition, the State Party to submit by 30 December 2013, the Action Plan relating to the project for the Citadel, coordinated by the World Heritage Centre in close collaboration with ISPAN;
11. Requests moreover the international community to ensure by every possible means, its support in the implementation of the recommendations to rapidly approve financial and human resources in order to assist the State Party to ensure the conservation of the entire property and in particular the quality of life of the inhabitants;
12. Finally, requests the State Party to submit to the World Heritage Centre, by 1 February 2014, an updated report on the state of conservation of the property and the implementation of the above recommendations, for examination by the World Heritage Committee at its 38th session in 2014.
Next 2014 Previous 2012
Nomination records (Year): 1981
Criteria: (iv)(vi)
WHC-13/37.COM/7B.Add